Last reviewed · How we verify
Amivantamab Intravenous
Amivantamab is a bispecific monoclonal antibody that simultaneously binds to EGFR and MET receptors, blocking their signaling and triggering immune-mediated tumor cell death.
Amivantamab is a bispecific monoclonal antibody that simultaneously binds to EGFR and MET receptors, blocking their signaling and triggering immune-mediated tumor cell death. Used for Non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, EGFR-mutant NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors.
At a glance
| Generic name | Amivantamab Intravenous |
|---|---|
| Also known as | JNJ-61186372, Chemotherapy |
| Sponsor | Janssen Research & Development, LLC |
| Drug class | Bispecific monoclonal antibody |
| Target | EGFR and MET |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Amivantamab targets two key oncogenic pathways by engaging both epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). By binding both receptors, it prevents ligand-induced activation and promotes antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), leading to direct tumor cell killing and immune activation.
Approved indications
- Non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations
- EGFR-mutant NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors
Common side effects
- Infusion-related reactions
- Rash
- Paronychia
- Diarrhea
- Nausea
- Fatigue
- Vomiting
Key clinical trials
- A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (PHASE2)
- A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions (PHASE3)
- A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer (PHASE1, PHASE2)
- A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer (PHASE1)
- A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer (PHASE3)
- A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer (PHASE1, PHASE2)
- A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer (PHASE1, PHASE2)
- A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amivantamab Intravenous CI brief — competitive landscape report
- Amivantamab Intravenous updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI